Ivosidenib Combination Demonstrates Real-World Efficacy in IDH1-Mutated AML, Matching Clinical Trial Results
核心洞察
The phase 3b ALIDHE trial showed ivosidenib plus azacitidine achieved a 58.4% objective response rate in 89 patients with newly diagnosed IDH1 (搜索)-mutated acute myeloid leukemia (搜索).
Real-world efficacy outcomes were comparable to the pivotal AGILE trial, which demonstrated a 62.5% objective response rate with the same combination therapy.
Complete responses occurred in 41.6% of patients in the real-world setting, with safety profiles consistent with previous clinical trial data.
The combination of ivosidenib (Tibsovo) and azacitidine (Vidaza) demonstrated promising real-world activity in patients with newly diagnosed IDH1 (搜索)-mutated acute myeloid leukemia (搜索) (AML), achieving efficacy outcomes comparable to those observed in the pivotal clinical trial that led to FDA approval. Results from the ongoing phase 3b ALIDHE trial (NCT05907057) were presented at the 2025 American Society of Hematology Annual Meeting and Exhibition.
Real-World Efficacy Mirrors Clinical Trial Results
Among 89 evaluable patients in the ALIDHE trial, the objective response rate (ORR) reached 58.4%. The response breakdown included complete responses (CRs) in 41.6% of patients, CR with hematologic recovery (CRh) in 3.4%, CR with incomplete hematologic recovery in 7.9%, and partial responses (PRs) in 4.5%. These outcomes closely matched those from the phase 3 AGILE trial (NCT03173248), which showed an ORR of 62.5% among 72 evaluable patients.
"Preliminary findings from ALIDHE are consistent with the AGILE pivotal trial; ivosidenib [plus] azacitidine shows similar safety results, and efficacy outcomes are promising," wrote lead study author Paresh Vyas, MRCP, FRCP, FRCPath, from the MRC Molecular Haematology Unit in the Radcliffe Department of Medicine of Weatherall Institute of Molecular Medicine at the University of Oxford, along with coauthors.
Study Design and Patient Population
The ALIDHE study represents a post-approval real-world assessment of the ivosidenib combination, following FDA approval in May 2022 based on AGILE trial data. The study includes all patients with IDH1 (搜索)-mutated disease who are ineligible for intensive induction chemotherapy, providing a broader patient population than typically seen in controlled clinical trials.
Patients received oral ivosidenib at 500 mg once daily plus azacitidine at 75 mg/m² intravenously or subcutaneously for 7 days in each 28-day cycle. As of the May 5, 2025 data cutoff, 68 patients (76.4%) remained on treatment, with a median duration of therapy of 5.1 months (range, 0.2-14.9).
The patient population had a median age of 75.0 years (range, 51-84), with 57.3% being female. Most patients presented with de novo disease (58.4%) and an ECOG performance status of 1 (42.7%). The most common IDH1 (搜索) mutation allele variants were R132C (搜索) and R132H (搜索), with frequent co-occurring mutations in genes associated with epigenetics, chromatin regulation, differentiation, and splicing.
Safety Profile Consistent with Previous Data
Safety outcomes in the real-world setting remained consistent with the AGILE trial. Treatment-emergent adverse effects (TEAEs) occurred in 93.3% of ALIDHE patients compared to 98.6% in AGILE, with grade 3 or higher events in 80.9% versus 93.0%, respectively.
Common TEAEs in the ALIDHE versus AGILE populations included neutropenia (32.6% vs 28.2%), nausea (29.2% vs 42.3%), QT prolongation (23.6% vs 19.7%), and anemia (20.2% vs 31.0%). TEAEs leading to treatment interruption occurred in 23.6% of ALIDHE patients compared to 52.1% in AGILE, while discontinuation rates were 4.5% versus 26.8%, respectively.
Bridging Clinical Trials to Practice
The investigators emphasized that ALIDHE data will help translate efficacy to effectiveness, bridging the gap between clinical trials and clinical practice. The study's primary endpoints include treatment-emergent adverse effects, serious adverse events, adverse events of special interest, transfusion requirements, and infection rates. Secondary endpoints encompass event-free survival, responses, patient- or caregiver-reported outcomes, length of hospital stay, outpatient visits, and emergency room visits.
"ALIDHE is still enrolling; future analyses will focus on safety outcomes from extended follow-up, effectiveness, and quality of life," the authors noted. The ongoing nature of the study promises to provide additional insights into the long-term real-world performance of this FDA-approved combination therapy for patients with IDH1-mutated AML (搜索) who cannot tolerate intensive chemotherapy.